{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,3,8]],"date-time":"2024-03-08T00:39:25Z","timestamp":1709858365478},"reference-count":62,"publisher":"Impact Journals, LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aging"],"DOI":"10.18632\/aging.205634","type":"journal-article","created":{"date-parts":[[2024,3,7]],"date-time":"2024-03-07T21:49:22Z","timestamp":1709848162000},"source":"Crossref","is-referenced-by-count":0,"title":["FHND004 inhibits malignant proliferation of multiple myeloma by targeting PDZ-binding kinase in MAPK pathway"],"prefix":"10.18632","author":[{"given":"Hongjie","family":"Wu","sequence":"first","affiliation":[{"name":"Nanjing Hospital of Chinese Medicine Affiliated to Nanjing University of Chinese Medicine, Nanjing, China"},{"name":"School of Medicine and Holistic Integrative Medicine, Nanjing University of Chinese Medicine, Nanjing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinjun","family":"Qian","sequence":"additional","affiliation":[{"name":"School of Medicine and Holistic Integrative Medicine, Nanjing University of Chinese Medicine, Nanjing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lianxin","family":"Zhou","sequence":"additional","affiliation":[{"name":"School of Medicine and Holistic Integrative Medicine, Nanjing University of Chinese Medicine, Nanjing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tingting","family":"Hu","sequence":"additional","affiliation":[{"name":"School of Medicine and Holistic Integrative Medicine, Nanjing University of Chinese Medicine, Nanjing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuanjiao","family":"Zhang","sequence":"additional","affiliation":[{"name":"School of Medicine and Holistic Integrative Medicine, Nanjing University of Chinese Medicine, Nanjing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chen","family":"Wang","sequence":"additional","affiliation":[{"name":"School of Medicine and Holistic Integrative Medicine, Nanjing University of Chinese Medicine, Nanjing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ye","family":"Yang","sequence":"additional","affiliation":[{"name":"School of Medicine and Holistic Integrative Medicine, Nanjing University of Chinese Medicine, Nanjing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunyan","family":"Gu","sequence":"additional","affiliation":[{"name":"Nanjing Hospital of Chinese Medicine Affiliated to Nanjing University of Chinese Medicine, Nanjing, China"},{"name":"School of Medicine and Holistic Integrative Medicine, Nanjing University of Chinese Medicine, Nanjing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"7892","published-online":{"date-parts":[[2024,3,7]]},"reference":[{"key":"1","doi-asserted-by":"publisher","first-page":"17046","DOI":"10.1038\/nrdp.2017.46","article-title":"Multiple myeloma.","volume":"3","author":"Anderson","year":"2017","journal-title":"Nat Rev Dis Primers"},{"key":"2","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1016\/S0140-6736(14)60493-1","article-title":"Multiple myeloma.","volume":"38","author":"Bornh\u00e4user","year":"2015","journal-title":"Lancet"},{"key":"3","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s40164-022-00303-z","article-title":"Metabolic cross-talk within the bone marrow milieu: focus on multiple myeloma.","volume":"1","author":"Menu","year":"2022","journal-title":"Exp Hematol Oncol"},{"key":"4","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21332","article-title":"Cancer statistics, 2016.","volume":"6","author":"Jemal","year":"2016","journal-title":"CA Cancer J Clin"},{"key":"5","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/S0140-6736(21)00135-5","article-title":"Multiple myeloma.","volume":"39","author":"Yong","year":"2021","journal-title":"Lancet"},{"key":"6","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1111\/bjh.15116","article-title":"Investigational agents in immunotherapy: a new horizon for the treatment of multiple myeloma.","volume":"18","author":"Richardson","year":"2018","journal-title":"Br J Haematol"},{"key":"7","first-page":"1972","article-title":"Approval summary: imatinib mesylate capsules for treatment of adult patients with newly diagnosed philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase.","volume":"9","author":"Pazdur","year":"2003","journal-title":"Clin Cancer Res"},{"key":"8","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1634\/theoncologist.8-4-303","article-title":"FDA drug approval summary: gefitinib (ZD1839) (Iressa) tablets.","volume":"8","author":"Pazdur","year":"2003","journal-title":"Oncologist"},{"key":"9","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.tcb.2013.11.002","article-title":"EGF receptor trafficking: consequences for signaling and cancer.","volume":"2","author":"Eden","year":"2014","journal-title":"Trends Cell Biol"},{"key":"10","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.phrs.2018.11.014","article-title":"Small molecule inhibitors targeting the EGFR\/ErbB family of protein-tyrosine kinases in human cancers.","volume":"13","author":"Roskoski","year":"2019","journal-title":"Pharmacol Res"},{"key":"11","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1158\/2159-8290.CD-20-1683","article-title":"Mobocertinib (TAK-788): A Targeted Inhibitor ofExon 20 Insertion Mutants in Non-Small Cell Lung Cancer.","volume":"1","author":"Greenfield","year":"2021","journal-title":"Cancer Discov"},{"key":"12","doi-asserted-by":"publisher","first-page":"e447","DOI":"10.1016\/S1470-2045(15)00246-6","article-title":"Treatment approaches for EGFR-inhibitor-resistant patients with non-small-cell lung cancer.","volume":"1","author":"Pacey","year":"2015","journal-title":"Lancet Oncol"},{"key":"13","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1158\/2159-8290.CD-14-0337","article-title":"AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer.","volume":"4","author":"Jacobs","year":"2014","journal-title":"Cancer Discov"},{"key":"14","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1056\/NEJMoa1411817","article-title":"AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer.","volume":"37","author":"Kim","year":"2015","journal-title":"N Engl J Med"},{"key":"15","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1038\/nrclinonc.2014.104","article-title":"Acquired resistance to TKIs in solid tumours: learning from lung cancer.","volume":"1","author":"Sequist","year":"2014","journal-title":"Nat Rev Clin Oncol"},{"key":"16","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1517\/14656566.2014.909412","article-title":"Protein kinase inhibitors to treat non-small-cell lung cancer.","volume":"1","author":"Cappuzzo","year":"2014","journal-title":"Expert Opin Pharmacother"},{"key":"17","doi-asserted-by":"publisher","first-page":"577","DOI":"10.3389\/fphar.2018.00577","article-title":"AnAssay of hERG KChannel Potency for a New EGFR Inhibitor FHND004.","volume":"9","author":"Zhang","year":"2018","journal-title":"Front Pharmacol"},{"key":"18","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.ejmech.2017.04.036","article-title":"Design, synthesis, SAR discussion,andevaluation of novel selective EGFR modulator to inhibit L858R\/T790M double mutants.","volume":"13","author":"Jin","year":"2017","journal-title":"Eur J Med Chem"},{"key":"19","doi-asserted-by":"publisher","first-page":"800","DOI":"10.3389\/fonc.2019.00800","article-title":"Rethink of EGFR in Cancer With Its Kinase Independent Function on Board.","volume":"9","author":"Weihua","year":"2019","journal-title":"Front Oncol"},{"key":"20","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1002\/cac2.12005","article-title":"Spectrum of EGFR aberrations and potential clinical implications: insights from integrative pan-cancer analysis.","volume":"4","author":"Sun","year":"2020","journal-title":"Cancer Commun (Lond)"},{"key":"21","doi-asserted-by":"publisher","first-page":"9925","DOI":"10.1038\/srep09925","article-title":"Multiple myeloma acquires resistance to EGFR inhibitor via induction of pentose phosphate pathway.","volume":"5","author":"Chen","year":"2015","journal-title":"Sci Rep"},{"key":"22","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1038\/s41467-019-08902-x","article-title":"ABHD5 blunts the sensitivity of colorectal cancer to fluorouracil via promoting autophagic uracil yield.","volume":"1","author":"Xie","year":"2019","journal-title":"Nat Commun"},{"key":"23","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1161\/CIRCRESAHA.119.315861","article-title":"Celastrol Attenuates Angiotensin II-Induced Cardiac Remodeling by Targeting STAT3.","volume":"12","author":"Liang","year":"2020","journal-title":"Circ Res"},{"key":"24","doi-asserted-by":"publisher","first-page":"15084","DOI":"10.1073\/pnas.1521316112","article-title":"Systematic identification of arsenic-binding proteins reveals that hexokinase-2 is inhibited by arsenic.","volume":"11","author":"Wu","year":"2015","journal-title":"Proc Natl Acad Sci USA"},{"key":"25","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1007\/s12291-012-0222-y","article-title":"Assessment of oxidative stress and inflammatory process in patients of multiple myeloma.","volume":"2","author":"Saxena","year":"2012","journal-title":"Indian J Clin Biochem"},{"key":"26","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1080\/08820139.2016.1208219","article-title":"Effect of Cytokine Genes in the Pathogenesis and on the Clinical Parameters for the Treatment of Multiple Myeloma.","volume":"4","author":"Pehl\u0131van","year":"2017","journal-title":"Immunol Invest"},{"key":"27","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1016\/j.ejca.2006.02.017","article-title":"Angiogenesis in multiple myeloma.","volume":"4","author":"Sezer","year":"2006","journal-title":"Eur J Cancer"},{"key":"28","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s13045-018-0689-y","article-title":"Multiple myeloma-derived exosomes are enriched of amphiregulin (AREG) and activate the epidermal growth factor pathway in the bone microenvironment leading to osteoclastogenesis.","volume":"1","author":"Alessandro","year":"2019","journal-title":"J Hematol Oncol"},{"key":"29","doi-asserted-by":"publisher","first-page":"4462","DOI":"10.3390\/ijms22094462","article-title":"The Role of Marrow Microenvironment in the Growth and Development of Malignant Plasma Cells in Multiple Myeloma.","volume":"2","author":"Terpos","year":"2021","journal-title":"Int J Mol Sci"},{"key":"30","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1111\/imr.12233","article-title":"Targeting the bone marrow microenvironment in multiple myeloma.","volume":"26","author":"Ghobrial","year":"2015","journal-title":"Immunol Rev"},{"key":"31","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1182\/blood-2003-05-1510","article-title":"An inhibitor of the EGF receptor family blocks myeloma cell growth factor activity of HB-EGF and potentiates dexamethasone or anti-IL-6 antibody-induced apoptosis.","volume":"10","author":"Klein","year":"2004","journal-title":"Blood"},{"key":"32","doi-asserted-by":"publisher","first-page":"3512","DOI":"10.1038\/sj.onc.1208536","article-title":"Expression of EGF-family receptors and amphiregulin in multiple myeloma. Amphiregulin is a growth factor for myeloma cells.","volume":"2","author":"Baudard","year":"2005","journal-title":"Oncogene"},{"key":"33","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.canlet.2016.11.008","article-title":"EAI045: The fourth-generation EGFR inhibitor overcoming T790M and C797S resistance.","volume":"38","author":"Liu","year":"2017","journal-title":"Cancer Lett"},{"key":"34","doi-asserted-by":"publisher","first-page":"371","DOI":"10.3390\/cells10020371","article-title":"PBK\/TOPK: A Therapeutic Target Worthy of Attention.","volume":"1","author":"Luo","year":"2021","journal-title":"Cells"},{"key":"35","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1038\/s41419-018-1131-7","article-title":"T-LAK cell-originated protein kinase (TOPK): an emerging target for cancer-specific therapeutics.","volume":"9","author":"Higgins","year":"2018","journal-title":"Cell Death Dis"},{"key":"36","doi-asserted-by":"publisher","first-page":"21525","DOI":"10.1074\/jbc.M909629199","article-title":"Cloning and expression of a novel MAPKK-like protein kinase, lymphokine-activated killer T-cell-originated protein kinase, specifically expressed in the testis and activated lymphoid cells.","volume":"27","author":"Ueda","year":"2000","journal-title":"J Biol Chem"},{"key":"37","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1111\/j.1349-7006.2009.01400.x","article-title":"Critical roles of T-LAK cell-originated protein kinase in cytokinesis.","volume":"10","author":"Katagiri","year":"2010","journal-title":"Cancer Sci"},{"key":"38","doi-asserted-by":"publisher","first-page":"3451","DOI":"10.1038\/sj.onc.1210142","article-title":"PBK\/TOPK promotes tumour cell proliferation through p38 MAPK activity and regulation of the DNA damage response.","volume":"2","author":"O\u2019connor","year":"2007","journal-title":"Oncogene"},{"key":"39","doi-asserted-by":"publisher","first-page":"e0204866","DOI":"10.1371\/journal.pone.0204866","article-title":"Cytoplasmic, nuclear, and total PBK\/TOPK expression is associated with prognosis in colorectal cancer patients: A retrospective analysis based on immunohistochemistry stain of tissue microarrays.","volume":"1","author":"Chen","year":"2018","journal-title":"PLoS One"},{"key":"40","doi-asserted-by":"publisher","first-page":"29601","DOI":"10.1074\/jbc.M111.225813","article-title":"T-LAK cell-originated protein kinase (TOPK) phosphorylation of MKP1 protein prevents solar ultraviolet light-induced inflammation through inhibition of the p38 protein signaling pathway.","volume":"28","author":"Dong","year":"2011","journal-title":"J Biol Chem"},{"key":"41","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1111\/j.1440-169X.2005.00834.x","article-title":"Expression and phosphorylation of TOPK during spermatogenesis.","volume":"4","author":"Kito","year":"2005","journal-title":"Dev Growth Differ"},{"key":"42","doi-asserted-by":"publisher","first-page":"22460","DOI":"10.18632\/oncotarget.7984","article-title":"Pantoprazole, an FDA-approved proton-pump inhibitor, suppresses colorectal cancer growth by targeting T-cell-originated protein kinase.","volume":"7","author":"Duan","year":"2016","journal-title":"Oncotarget"},{"key":"43","doi-asserted-by":"publisher","first-page":"801","DOI":"10.3892\/ijo.2018.4427","article-title":"Mitotic kinase PBK\/TOPK as a therapeutic target for adult T-cell leukemia\/lymphoma.","volume":"5","author":"Mori","year":"2018","journal-title":"Int J Oncol"},{"key":"44","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.21037\/gs-22-449","article-title":"Identification of biomarkers related to tumorigenesis and prognosis in breast cancer.","volume":"1","author":"Yi","year":"2022","journal-title":"Gland Surg"},{"key":"45","doi-asserted-by":"publisher","first-page":"988","DOI":"10.3390\/jpm11100988","article-title":"RNA-Sequencing-Based Transcriptomic Score with Prognostic and Theranostic Values in Multiple Myeloma.","volume":"1","author":"Moreaux","year":"2021","journal-title":"J Pers Med"},{"key":"46","doi-asserted-by":"publisher","first-page":"784","DOI":"10.3324\/haematol.2018.208306","article-title":"Kinome expression profiling to target new therapeutic avenues in multiple myeloma.","volume":"10","author":"Moreaux","year":"2020","journal-title":"Haematologica"},{"key":"47","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1002\/cam4.2695","article-title":"Potent anti-myeloma activity of the TOPK inhibitor OTS514 in pre-clinical models.","volume":"9","author":"Jakubowiak","year":"2020","journal-title":"Cancer Med"},{"key":"48","doi-asserted-by":"publisher","first-page":"4474","DOI":"10.1182\/blood-2018-99-119186","article-title":"PDZ Binding Kinase (PBK) - a Novel Gene Driving Genomic Evolution in Multiple Myeloma.","volume":"13","author":"Munshi","year":"2018","journal-title":"Blood"},{"key":"49","doi-asserted-by":"publisher","first-page":"6884","DOI":"10.1158\/1078-0432.CCR-06-0410","article-title":"Lymphokine-activated killer T-cell-originated protein kinase phosphorylation of histone H2AX prevents arsenite-induced apoptosis in RPMI7951 melanoma cells.","volume":"1","author":"Dong","year":"2006","journal-title":"Clin Cancer Res"},{"key":"50","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1053\/j.gastro.2007.04.048","article-title":"Bidirectional signals transduced by TOPK-ERK interaction increase tumorigenesis of HCT116 colorectal cancer cells.","volume":"13","author":"Dong","year":"2007","journal-title":"Gastroenterology"},{"key":"51","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1002\/gcc.20795","article-title":"Critical roles of LGN\/GPSM2 phosphorylation by PBK\/TOPK in cell division of breast cancer cells.","volume":"4","author":"Nakamura","year":"2010","journal-title":"Genes Chromosomes Cancer"},{"key":"52","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.leukres.2012.11.010","article-title":"c-Myc and E2F1 drive PBK\/TOPK expression in high-grade malignant lymphomas.","volume":"3","author":"Rapoport","year":"2013","journal-title":"Leuk Res"},{"key":"53","doi-asserted-by":"publisher","first-page":"2389","DOI":"10.1038\/onc.2011.419","article-title":"TOPK\/PBK promotes cell migration via modulation of the PI3K\/PTEN\/AKT pathway and is associated with poor prognosis in lung cancer.","volume":"3","author":"Lai","year":"2012","journal-title":"Oncogene"},{"key":"54","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1002\/2211-5463.12855","article-title":"PBK attenuates paclitaxel-induced autophagic cell death by suppressing p53 in H460 non-small-cell lung cancer cells.","volume":"1","author":"Oh","year":"2020","journal-title":"FEBS Open Bio"},{"key":"55","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1038\/s12276-022-00809-w","article-title":"PBK drives PARP inhibitor resistance through the TRIM37\/NF\u03baB axis in ovarian cancer.","volume":"5","author":"Kong","year":"2022","journal-title":"Exp Mol Med"},{"key":"56","doi-asserted-by":"publisher","first-page":"3585","DOI":"10.1074\/jbc.M112.422170","article-title":"Phosphorylation of I\u03baB\u03b1 at serine 32 by T-lymphokine-activated killer cell-originated protein kinase is essential for chemoresistance against doxorubicin in cervical cancer cells.","volume":"28","author":"Oh","year":"2013","journal-title":"J Biol Chem"},{"key":"57","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1038\/s41419-019-1415-6","article-title":"PBK, targeted by EVI1, promotes metastasis and confers cisplatin resistance through inducing autophagy in high-grade serous ovarian carcinoma.","volume":"1","author":"Kong","year":"2019","journal-title":"Cell Death Dis"},{"key":"58","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.pharmthera.2013.10.001","article-title":"MEK in cancer and cancer therapy.","volume":"14","author":"Raymond","year":"2014","journal-title":"Pharmacol Ther"},{"key":"59","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1007\/s11010-021-04329-5","article-title":"The role of T-LAK cell-originated protein kinase in targeted cancer therapy.","volume":"47","author":"Zhu","year":"2022","journal-title":"Mol Cell Biochem"},{"key":"60","doi-asserted-by":"publisher","first-page":"3043","DOI":"10.1182\/blood-2014-07-552059","article-title":"Curing myeloma at last: defining criteria and providing the evidence.","volume":"12","author":"Crowley","year":"2014","journal-title":"Blood"},{"key":"61","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1038\/leu.2015.334","article-title":"FOXM1 is a therapeutic target for high-risk multiple myeloma.","volume":"3","author":"Janz","year":"2016","journal-title":"Leukemia"},{"key":"62","doi-asserted-by":"publisher","first-page":"e684","DOI":"10.1002\/ctm2.684","article-title":"Splicing factor arginine\/serine-rich 8 promotes multiple myeloma malignancy and bone lesion through alternative splicing of CACYBP and exosome-based cellular communication.","volume":"1","author":"Yang","year":"2022","journal-title":"Clin Transl Med"}],"container-title":["Aging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.aging-us.com\/lookup\/doi\/10.18632\/aging.205634","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,7]],"date-time":"2024-03-07T21:49:27Z","timestamp":1709848167000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.aging-us.com\/lookup\/doi\/10.18632\/aging.205634"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,7]]},"references-count":62,"alternative-id":["205634"],"URL":"https:\/\/doi.org\/10.18632\/aging.205634","relation":{},"ISSN":["1945-4589"],"issn-type":[{"value":"1945-4589","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,7]]}}}